EP Patent

EP4611753A1 — Pim1 inhibitor for treating myeloproliferative neoplasms

Assigned to Sumitomo Pharma America Inc · Expires 2025-09-10 · 1y expired

What this patent protects

Methods for treatment of myeloproliferative neoplasms are provided, particularly in patients with poor bone marrow functioning, and difficult to treat human patients such as those with relapsed or refractory disease. The disclosed methods comprise administering Compound (1) havin…

USPTO Abstract

Methods for treatment of myeloproliferative neoplasms are provided, particularly in patients with poor bone marrow functioning, and difficult to treat human patients such as those with relapsed or refractory disease. The disclosed methods comprise administering Compound (1) having the following structure or a pharmaceutically acceptable salt thereof, and optionally a JAK kinase inhibitor and/or ACVR inhibitor, to a human subject in need thereof.

Drugs covered by this patent

Patent Metadata

Patent number
EP4611753A1
Jurisdiction
EP
Classification
—
Expires
2025-09-10
Drug substance claim
No
Drug product claim
No
Assignee
Sumitomo Pharma America Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.